01—Abstract
Summary
Summary of the 8-K filed October 24, 2024. Cited figures are marked; the original filing is the authoritative source.
West Pharmaceutical Services, Inc. (NYSE: WST) reported third-quarter 2024 net sales of $746.9 milliona, a decline of 0.1%, with organic net sales declining 0.5%.
Reported diluted EPS was $1.85b, compared with $2.14 in the same period last year, and adjusted diluted EPS was $1.85 versus $2.16 a year earlier. Net income for the quarter was $136.0 million, compared with $161.3 million in the prior-year period. The Proprietary Products segment net sales declined 0.2% to $601.4 million, while the Contract-Manufactured Products segment grew 0.4% to $145.5 million.
The company raised its full-year 2024 net sales guidance to $2.875 billion to $2.905 billionc, up from $2.870 billion to $2.900 billion, citing favorable currency movements. It also raised full-year 2024 adjusted diluted EPS guidance to $6.55 to $6.75, from $6.35 to $6.65. The updated EPS range includes $0.26 from first nine-month 2024 tax benefits tied to stock-based compensation.
Full-year 2024 organic net sales are expected to decline approximately 1.5% to 2%, and capital spending guidance is unchanged at $375 milliond. Cash flow weakened over the first nine months of 2024.
Operating cash flow was $463.3 million, a decrease of 13.8%, and free cash flow fell 32.7% to $191.2 million as capital expenditures rose 7.4% to $272.1 million. The Board approved a fourth-quarter 2024 dividend of $0.21 per share, a 5.0% increase over the $0.20 paid in each of the prior four quarters, marking the thirty-second consecutive annual dividend increase.
02—Key points
Key Highlights
- Q3 2024 net sales of $746.9 million, down 0.1%; organic net sales down 0.5%
- Q3 2024 diluted EPS of $1.85 versus $2.14 a year earlier; adjusted diluted EPS of $1.85 versus $2.16
- Full-year 2024 net sales guidance raised to $2.875–$2.905 billion; adjusted diluted EPS guidance raised to $6.55–$6.75
- Full-year 2024 organic net sales expected to decline approximately 1.5% to 2%
- Operating cash flow fell 13.8% to $463.3 million for the first nine months; free cash flow declined 32.7% to $191.2 million
- Quarterly dividend increased 5.0% to $0.21 per share, the thirty-second consecutive annual increase
- Share repurchases of $506.5 million (1,409,786 shares) in the first nine months of 2024 at an average price of $359.24
03—Questions
Frequently Asked Questions
Why did West raise its full-year 2024 guidance?
The company attributed the net sales guidance increase to favorable currency movements, which raised the range to $2.875 billion–$2.905 billion. The adjusted diluted EPS guidance increase to $6.55–$6.75 also reflects a smaller foreign currency headwind of $0.02, compared with $0.03 previously, and $0.26 of first nine-month 2024 tax benefits from stock-based compensation.
How did the segments perform in the third quarter?
Proprietary Products net sales declined 0.2% to $601.4 million, with organic net sales down 0.5%, driven by lower Generics and Biologics volumes partly offset by Pharma growth. Contract-Manufactured Products net sales grew 0.4% to $145.5 million, led by self-injection devices for obesity and diabetes, offset by lower healthcare diagnostic device sales.
What happened to cash flow and capital spending?
For the first nine months of 2024, operating cash flow was $463.3 million, down 13.8%. Capital expenditures rose 7.4% to $272.1 million, so free cash flow fell 32.7% to $191.2 million. Full-year 2024 capital spending guidance is unchanged at $375 million.
What is the dividend announcement?
West's Board approved a fourth-quarter 2024 dividend of $0.21 per share, a 5.0% increase over the $0.20 paid in each of the four preceding quarters. It is payable November 20, 2024, to shareholders of record as of November 13, 2024, and marks the thirty-second consecutive annual dividend increase.
04—Continue